Spruce Biosciences Q1 2026 Earnings Report

Spruce Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$7.93
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Spruce Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Spruce Biosciences Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Spruce Biosciences (NASDAQ:SPRB) is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels. In parallel, Spruce is developing nevanimibe, an adrenocortical hormone synthesis inhibitor, to further address the hormonal imbalances associated with CAH. Both candidates have demonstrated promising safety and efficacy profiles in early-phase studies.

Since its founding in 2017, Spruce Biosciences has established a global clinical infrastructure with trial sites across North America and Europe, enabling the company to enroll patients in its pivotal studies efficiently. The company collaborates with academic centers and patient advocacy groups to support trial design and patient recruitment, underscoring its commitment to advancing care for individuals living with rare endocrine disorders.

Under the leadership of President and Chief Executive Officer Jonathan Porges, Spruce combines experienced management with a scientific advisory board comprised of experts in endocrinology and drug development. The company’s deliberate strategy of targeting well-defined patient populations aims to streamline regulatory pathways and bring transformative therapies to market for communities with few existing treatment options.